{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:03:37Z","timestamp":1793819017914,"version":"4.6.1"},"reference-count":128,"publisher":"Informa UK Limited","issue":"1","funder":[{"name":"This manuscript was not funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2022,1,2]]},"DOI":"10.1080\/14656566.2021.1959914","type":"journal-article","created":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T05:56:40Z","timestamp":1629957400000},"page":"63-89","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["The pharmacotherapeutic management of duodenal and gastric ulcers"],"prefix":"10.1080","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1976-6789","authenticated-orcid":false,"given":"Taraneh","family":"Mousavi","sequence":"first","affiliation":[{"name":"Toxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), the Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran"},{"name":"Department of Toxicology and Pharmacology, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5206-6197","authenticated-orcid":false,"given":"Shekoufeh","family":"Nikfar","sequence":"additional","affiliation":[{"name":"Personalized Medicine Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran"},{"name":"Evidence-Based Evaluation of Cost-Effectiveness and Clinical Outcomes Group, Pharmaceutical Sciences Research Center (PSRC), and the Pharmaceutical Management and Economics Research Center (PMERC), the Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran"},{"name":"Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0123-1209","authenticated-orcid":false,"given":"Mohammad","family":"Abdollahi","sequence":"additional","affiliation":[{"name":"Toxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), the Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran"},{"name":"Department of Toxicology and Pharmacology, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran"},{"name":"Personalized Medicine Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,8,26]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1007\/s11938-020-00277-z"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32404-7"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.03960.x"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.04.022"},{"key":"cit0005","unstructured":"Peptic ulcer disease: Epidemiology, etiology, and pathogenesis Massachusetts: Up to Date; 2020 [cited 2021 Feb 06]. Available from: https:\/\/www.uptodate.com\/contents\/peptic-ulcer-disease-epidemiology-etiology-and-pathogenesis"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-84628-833-3_48"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2153"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2018.12.009"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2013.08.022"},{"key":"cit0010","unstructured":"Peptic ulcer disease: Clinical manifestations and diagnosis Massachusetts: Up to Date; 2020 [cited 2021 Feb 06]. Available from: https:\/\/www.uptodate.com\/contents\/peptic-ulcer-disease-clinical-manifestations-and-diagnosis"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.03.013"},{"key":"cit0012","first-page":"9064952","volume":"2018","author":"Talebi Bezmin AA","year":"2018","journal-title":"J Pathog"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312288"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001594"},{"key":"cit0015","unstructured":"Indications and diagnostic tests for Helicobacter pylori infection Massachusetts: Up to Date; 2020 [cited 2021 Feb 06]. Available from: https:\/\/www.uptodate.com\/contents\/peptic-ulcer-disease-clinical-manifestations-and-diagnosis"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1586\/17474124.2016.1142872"},{"key":"cit0017","volume-title":"Applied therapeutics: the clinical use of drugs","author":"Zeind CS","year":"2018"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1531703"},{"key":"cit0019","unstructured":"Peptic ulcer disease: Treatment and secondary prevention Massachusetts: Up to Date; 2020 [cited 2021 Feb 06]. Available from: https:\/\/www.uptodate.com\/contents\/peptic-ulcer-disease-treatment-and-secondary-prevention"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-021-01769-0"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1586\/egh.12.18"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.5009\/gnl15502"},{"key":"cit0023","unstructured":"USFDA. AMOXIL maryland: Maryland; 2008 [cited 2021 Feb 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/050542s24,050754s11,050760s10,050761s10lbl.pdf"},{"key":"cit0024","unstructured":"USFDA. BIAXIN\u00ae filmtab\u00ae maryland: u.s. food and drug administration; 2009 [cited 2021 Feb 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/050662s042,050698s024,050775s013lbl.pdf"},{"key":"cit0025","unstructured":"USFDA. DORYX\u00ae (doxycycline hyclate) maryland: u.s. food and drug administration; 2008 [cited 2021 Feb 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/050795s005lbl.pdf"},{"key":"cit0026","unstructured":"USFDA. LEVAQUIN\u00ae (levofloxacin) tablets maryland: u.s. food and drug administration; 1996 [cited 2021 Feb 13]. Available from: https:\/\/www.fda.gov\/files\/drugs\/published\/Levaquin-Label.pdf"},{"key":"cit0027","unstructured":"USFDA. FLAGYL\u00ae(metronidazole) capsules Maryland: u.S. Food and Drug Administration; 2013 [cited 2021 Feb 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/020334s008lbl.pdf"},{"key":"cit0028","unstructured":"USFDA. Flagyl\u00ae metronidazole tablets maryland: u.s. food and drug administration; 2010 [cited 2021 Feb 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/012623s061lbl.pdf"},{"key":"cit0029","unstructured":"USFDA. ALINIA\u00ae (nitazoxanide) maryland: u.s. food and drug administration; 2016 [cited 2021 Febraury 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021497s001,021498s004lbl.pdf"},{"key":"cit0030","unstructured":"USFDA. Rifabutin capsules maryland: u.s. food and drug administration; 2008 [cited 2021 Feb 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/050689s016lbl.pdf"},{"key":"cit0031","unstructured":"Tetracyclines Massachusetts Up To Date 2021 [cited 2021 Feb 13]. Available from: https:\/\/www.uptodate.com\/contents\/tetracyclines#H5"},{"key":"cit0032","unstructured":"USFDA. Tindamax (tinidazole tablets) maryland: u.s. food and drug administration; 2004 [cited 2021 Feb 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/21618_tindamax_lbl.pdf"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i17.5119"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.118.081570"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e3181e88515"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.639353"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000001186"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12667"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0532-9"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0724-1"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1016\/j.giec.2019.12.005"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30037-2"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2018.1450442"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.10.022"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2017.1284732"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-018-4788-y"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-017-0577-6"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1080\/14779072.2019.1615446"},{"key":"cit0049","unstructured":"Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders Massachusetts Up to Date; 2020 [cited 2021 Feb 13]. Available from: https:\/\/www.uptodate.com\/contents\/proton-pump-inhibitors-overview-of-use-and-adverse-effects-in-the-treatment-of-acid-related-disorders"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2318"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2018.02.010"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.c19-00084"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2020.1753406"},{"key":"cit0054","unstructured":"Lamont JT Bacteriology and epidemiology of helicobacter pylori infection massachusetts: Up to date; 2020 [cited 2021 Feb 06]. Available from: https:\/\/www.uptodate.com\/contents\/bacteriology-and-epidemiology-of-helicobacter-pylori-infection"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1556\/030.62.2015.3.6"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12365"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.11.010"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.2009.00737.x"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12531"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky401"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw118"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0818-1"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2009.01140.x"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i29.9898"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.563"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12633"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.2174\/13816128113196660728"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.04.006"},{"key":"cit0069","first-page":"1","volume-title":"Current treatment options in gastroenterology","author":"Saleem N","year":"2020"},{"key":"cit0070","unstructured":"Treatment regimens for Helicobacter pylori Massachusetts: Up to Date; 2020 [cited 2021 Feb 06]. Available from: https:\/\/www.uptodate.com\/contents\/treatment-regimens-for-helicobacter-pylori"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.2011.00896.x"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2011.584894"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i19.2377"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1007\/s12664-013-0304-7"},{"issue":"1","key":"cit0075","volume":"15","author":"Chan -C-C","year":"2015","journal-title":"BMC Gastroenterol"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.306"},{"issue":"6","key":"cit0077","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/jac\/dky056","volume":"73","author":"Xie Y","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"cit0078","first-page":"e00432","volume":"62","author":"Xie Y","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197096"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.3329\/bmrcb.v37i3.9118"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i46.13124"},{"key":"cit0082","unstructured":"Amoxicillin: Drug information Massachusetts: UpToDate; [cited 2021 17 February]. Available from: https:\/\/uptodatefree.ir\/topic.htm?path=amoxicillin-drug-information"},{"key":"cit0083","unstructured":"Amoxicillin: Patient drug information Massachusetts: UpToDate; [cited 2021 17 February]. Available from: https:\/\/uptodatefree.ir\/topic.htm?path=amoxicillin-patient-drug-information"},{"key":"cit0084","unstructured":"Bismuth subsalicylate: Drug information Massachusetts: UpToDate; 2021 [cited 2021 Feb 17]. Available from: https:\/\/uptodatefree.ir\/topic.htm?path=bismuth-subsalicylate-drug-information"},{"key":"cit0085","unstructured":"Bismuth subsalicylate: Patient drug information Massachusetts: UpToDate; 2021 [cited 2021 Feb 17]. Available from: https:\/\/uptodatefree.ir\/topic.htm?path=bismuth-subsalicylate-patient-drug-information"},{"key":"cit0086","unstructured":"Clarithromycin: Drug information massachusetts: UpToDate."},{"key":"cit0087","unstructured":"Clarithromycin: Patient drug information Massachusetts: UpToDate; [cited 2021 17 February]. Available from: https:\/\/uptodatefree.ir\/topic.htm?path=clarithromycin-patient-drug-information"},{"key":"cit0088","unstructured":"Doxycycline: Drug information Massachusetts: UpToDate; [cited 2021 17 February]. Available from: https:\/\/uptodatefree.ir\/topic.htm?path=doxycycline-drug-information"},{"key":"cit0089","unstructured":"Doxycycline: Patient drug information Massachusetts: UpToDate; [cited 2021 17 February]. Available from: https:\/\/uptodatefree.ir\/topic.htm?path=doxycycline-patient-drug-information"},{"key":"cit0090","unstructured":"Levofloxacin (systemic): Drug information Massachusetts: UpToDate; [cited 2021 17 February]. Available from: https:\/\/uptodatefree.ir\/topic.htm?path=levofloxacin-systemic-drug-information"},{"key":"cit0091","unstructured":"Levofloxacin (systemic): Patient drug information Massachusetts: UpToDate; [cited 2021 17 February]. Available from: https:\/\/uptodatefree.ir\/topic.htm?path=levofloxacin-systemic-patient-drug-information"},{"key":"cit0092","unstructured":"Metronidazole (systemic): Drug information Massachusetts: UpToDate; [cited 2021 17 February]. Available from: https:\/\/uptodatefree.ir\/topic.htm?path=metronidazole-systemic-drug-information"},{"key":"cit0093","unstructured":"Metronidazole (systemic): Patient drug information Massachusetts: UpToDate; [cited 2021 17 February]. Available from: https:\/\/uptodatefree.ir\/topic.htm?path=metronidazole-systemic-patient-drug-information"},{"key":"cit0094","unstructured":"Nitazoxanide: Drug information Massachusetts: UpToDate; [cited 2021 17 February]. Available from: https:\/\/uptodatefree.ir\/topic.htm?path=nitazoxanide-drug-information"},{"key":"cit0095","unstructured":"Nitazoxanide: Patient drug information Massachusetts: UpToDate; [cited 2021 17 February]. Available from: https:\/\/uptodatefree.ir\/topic.htm?path=nitazoxanide-patient-drug-information"},{"key":"cit0096","unstructured":"Rifabutin: Drug information Massachusetts: UpToDate; [cited 2021 17 February]. Available from: https:\/\/uptodatefree.ir\/topic.htm?path=rifabutin-drug-information"},{"key":"cit0097","unstructured":"Rifabutin: Patient drug information Massachusetts: UpToDate; [cited 2021 17 February]. Available from: https:\/\/uptodatefree.ir\/topic.htm?path=rifabutin-patient-drug-information"},{"key":"cit0098","unstructured":"Tetracycline: Drug information Massachusetts: UpToDate; [cited 2021 17 Februay]. Available from: https:\/\/uptodatefree.ir\/topic.htm?path=tetracycline-drug-information"},{"key":"cit0099","unstructured":"Tetracycline: Patient drug information: UpToDate; [cited 2021 17 February]. Available from: https:\/\/uptodatefree.ir\/topic.htm?path=tetracycline-patient-drug-information"},{"key":"cit0100","unstructured":"Tinidazole: Drug information Massachusetts: UpToDate; [cited 2021 17 February]. Available from: https:\/\/uptodatefree.ir\/topic.htm?path=tinidazole-drug-information"},{"key":"cit0101","unstructured":"Tinidazole: Patient drug information Massachusetts: UpToDate; [cited 2021 17 February]. Available from: https:\/\/uptodatefree.ir\/topic.htm?path=tinidazole-patient-drug-information"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2010.531485"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-017-4866-6"},{"key":"cit0104","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13876"},{"key":"cit0105","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1676722"},{"key":"cit0106","unstructured":"Organisation WG. World gastroenterology organisation global guidelines: probiotics and prebiotics wisconsin, United States: World gastroenterology organisation 2017 [cited 2021 May 03]. Available from: https:\/\/www.worldgastroenterology.org\/guidelines\/global-guidelines\/probiotics-and-prebiotics\/probiotics-and-prebiotics-english"},{"key":"cit0107","doi-asserted-by":"publisher","DOI":"10.1016\/j.cimid.2019.02.010"},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2020.1767067"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2020.1825682"},{"key":"cit0110","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2015.12.003"},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805819"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60900-9"},{"key":"cit0113","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.1.33"},{"key":"cit0114","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03530290046036"},{"key":"cit0115","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-012-0541-z"},{"key":"cit0116","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.115"},{"key":"cit0117","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.06.007"},{"key":"cit0118","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13642"},{"key":"cit0119","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04378.x"},{"key":"cit0120","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.555756"},{"key":"cit0121","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.443"},{"key":"cit0122","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-013-0113-x"},{"key":"cit0123","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.191087"},{"key":"cit0124","unstructured":"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity Massachusetts: Up to Date; 2019 [cited 2021 Feb 06]. Available from: https:\/\/www.uptodate.com\/contents\/nsaids-including-aspirin-primary-prevention-of-gastroduodenal-toxicity"},{"key":"cit0125","unstructured":"NSAIDs (including aspirin): Treatment of gastroduodenal toxicity Massachusetts: Up to Date; 2020 [cited 2021 Feb 06]. Available from: https:\/\/www.uptodate.com\/contents\/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity"},{"key":"cit0126","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2015.30.5.559"},{"key":"cit0127","doi-asserted-by":"publisher","DOI":"10.1159\/000323958"},{"key":"cit0128","unstructured":"Vakil NB Unusual causes of peptic ulcer disease 2020 [cited 2021 Apr 30]. Available from: https:\/\/www.uptodate.com\/contents\/unusual-causes-of-peptic-ulcer-disease"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2021.1959914","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T14:10:26Z","timestamp":1642083026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2021.1959914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,26]]},"references-count":128,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,2]]}},"alternative-id":["10.1080\/14656566.2021.1959914"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2021.1959914","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}